Ivan P. Tesakov

Ivan P. Tesakov

Auto-generated profile, based on publicly available information

Ivan P. Tesakov

Department of Oncology, Hematology, Clinical Immunology, and Rheumatology University Hospital Tuebingen Tuebingen Germany

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
AMAlexey Martyanov
Alexey Martyanov
ITIvan P. Tesakov
Ivan P. Tesakov
LKLili A. Khachatryan
Lili A. Khachatryan
OAOlga I. An
Olga I. An
ABAnna E. Boldova
Anna E. Boldova
Anastasia SveshnikovaAnastasia Sveshnikova
Anastasia Sveshnikova
Kaposiform hemangioendothelioma (KHE) is a rare vascular tumor of infancy that is commonly associated with a life-threatening thrombocytopenic condition, Kasabach-Merritt phenomenon (KMP). Platelet CLEC-2, tumor podoplanin interaction is considered the key mechanism of platelet clearance in these patients. Here, we aimed to assess platelet functionality in such patients. Three groups of 6 to 9 children were enrolled: group A with KHE/KMP without hematologic response (HR) to therapy; group B with KHE/KMP with HR; and group C with healthy children. Platelet functionality was assessed by continuous and end point flow cytometry, low-angle light scattering analysis (LaSca), fluorescent microscopy of blood smears, and ex vivo thrombi formation. Platelet integrin activation in response to a combination of CRP (GPVI agonist) and TRAP-6 (PAR1 agonist), as well as calcium mobilization and integrin activation in response to CRP or rhodocytin (CLEC-2 agonist) alone, were significantly diminished in groups A and B. At the same time, platelet responses to ADP with or without TRAP-6 were unaltered. Thrombi formation from collagen in parallel plate flow chambers was also noticeably decreased in groups A and B. In silico analysis of these results predicted diminished amounts of CLEC-2 on the platelet surface of patients, which was further confirmed by immunofluorescence microscopy and flow cytometry. In addition, we also noted a decrease in GPVI levels on platelets from group A. In KHE/KMP, platelet responses induced by CLEC-2 or GPVI activation are impaired because of the diminished number of receptors on the platelet surface. This impairment correlates with the severity of the disease and resolves as the patient recovers.

21 April 2021 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
ITI. P. Tesakov
I. P. Tesakov
AMAlexey Martyanov
Alexey Martyanov
ADAlexander E. Druy
Alexander E. Druy
Anastasia SveshnikovaAnastasia Sveshnikova
Anastasia Sveshnikova
Nowadays much attention is paid to non-invasive methods of cancer diagnostics and monitoring. One of the promising methods is the sequencing of platelet RNA (tumor-educated platelets), in which, as it was previously established, the mRNA repertoire changes in various oncological diseases. Thus, platelets can contain information about the molecular genetic characteristics of tumor. This review summarizes the current understanding of the mechanisms of interaction between tumor cells and platelets, and also discusses the possibilities of using platelet transcriptome analysis methods for diagnosing and assessing the dynamics of the tumor state, in particular, in response to therapy, as well as the current limitations for a wide range of introduction of this method into clinical practice.

5 August 2025 in Journal of Molecular Medicine
Verified
Journal Article
Closed access
PDF file
ITIvan Tesakov
Ivan Tesakov
AKAnna D. Korneichuk
Anna D. Korneichuk
AFAleksandra A. Filkova
Aleksandra A. Filkova
ABAnna E. Boldova
Anna E. Boldova
ADAnna A. Deputatova
Anna A. Deputatova
Anastasia SveshnikovaAnastasia Sveshnikova
Anastasia Sveshnikova

28 April 2026 in British Journal of Haematology
Verified
Journal Article
Open access
ITIvan P. Tesakov
Ivan P. Tesakov
JKJulia‐Jessica D. Korobkin
Julia‐Jessica D. Korobkin
DFDaria V. Fedorova
Daria V. Fedorova
SGSofia V. Galkina
Sofia V. Galkina
MGMaria M. Golomysova
Maria M. Golomysova
Anastasia SveshnikovaAnastasia Sveshnikova
Anastasia Sveshnikova
Summary: ETV6‐related thrombocytopenia (ETV6‐RT) is an inherited platelet disorder caused by germline ETV6 variants. Despite recent progress, the mechanisms underlying platelet dysfunction in ETV6‐RT remain unclear. We investigated 12 patients from six families using functional assays, electron microscopy, quantitative proteomics and cytoskeletal imaging. Most patients exhibited mild‐to‐moderate thrombocytopenia with variable paediatric bleeding symptoms (median International Society on Thrombosis and Haemostasis Bleeding Assessment Tool 3, range 1–9) but consistently mild bleeding in adulthood (median 0, range 0–1). Ex vivo thrombus formation was reduced independent of platelet count. Electron microscopy revealed defective platelet shape maintenance, characterized by spheroid morphology, reduced D max / D min ratios and diminished alpha‐granule pools. Flow cytometry and single‐platelet total internal reflection fluorescence imaging demonstrated largely preserved calcium signalling but impaired activation‐dependent shape change, dense‐granule release and integrin activation. Proteomics showed reduced alpha‐granule and lysosomal proteins alongside imbalanced regulators of actin remodelling and β‐tubulin. Phalloidin staining confirmed impaired actin cytoskeletal remodelling with reduced lamellipodia formation, while immunofluorescence revealed abnormal β1‐tubulin localization with disrupted marginal bands and reduced lysosome‐associated membrane protein 1 (LAMP1) expression. Additionally, granulocyte recruitment and migration within thrombi were impaired, suggesting broader thromboinflammatory defects. These findings suggest that combined disruption of cytoskeletal integrity and granule biogenesis underlies impaired thrombus formation in ETV6‐RT, providing mechanistic insight into the haemostatic defects associated with this disorder.

3 October 2023 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
ITI. P. Tesakov
I. P. Tesakov
EDE. A. Deordieva
E. A. Deordieva
TBT. G. Brontveyn
T. G. Brontveyn
Anastasia SveshnikovaAnastasia Sveshnikova
Anastasia Sveshnikova
Shwachman–Diamond syndrome is a rare genetic disorder with an autosomal recessive inheritance pattern. Most often (in more than 90% of cases) this disease is caused by biallelic pathogenic variants in the highly conserved SBDS gene located on the long arm of chromosome 7. However, approximately 10% of patients with the clinical phenotype of Shwachman–Diamond syndrome lack mutations in SBDS but have pathogenic variants in other genes, such as DNAJC21 or EFL1. Shwachman–Diamond syndrome is a multisystemic disorder characterized by exocrine pancreatic insufficiency, protein-energy undernutrition, delayed physical development, cognitive disorders, anomalies of the skeletal system, and immunological disorders. In addition to the described symptoms, Shwachman–Diamond syndrome is characterized by the presence of bone marrow failure (most often neutropenia and anemia), as well as an increased risk of cytogenetic abnormalities and a predisposition to myelodysplastic syndromes and acute myeloid leukemia. In this review, the authors summarize the spectrum of hematological disorders observed in Shwachman–Diamond syndrome, as well as describe the molecular mechanisms underlying them.